μ-imido-dicarbonic acid dibutyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: μ-imido-dicarbonic acid dibutyl ester
• 英文别名: μ-Imido-dikohlensaeure-dibutylester；Iminodicarbonsaeure-dibutylester；Azamalonsaeure-dibutylester；butyl N-butoxycarbonylcarbamate
• 化学式: C₁₀H₁₉NO₄
• 分子量: 217.265
• InChiKey: VGKYDZJUXJQEQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  四氯化碳 、 氯甲酸丁酯 、 alkaline earth salt of/the/ methylsulfuric acid 生成 μ-imido-dicarbonic acid ethyl ester-butyl ester 、 μ-imido-dicarbonic acid dibutyl ester 、 亚胺二乙酸二乙酯
  参考文献：
  名称：

  Slimowicz; Degering, Journal of the American Chemical Society, 1949, vol. 71, p. 1044

  摘要：

  DOI：

文献信息

• [EN] ANTI-EGFR ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENT-ANTICORPS ANTI-EGFR
  申请人：ABBVIE INC

  公开号：WO2017214301A1

  公开（公告）日：2017-12-14

  The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

  本发明涉及抑制Bcl-xL的抗表皮生长因子受体（EGFR）抗体药物偶联物（ADCs），包括所述ADCs的组成物和使用方法。
• OXAZOLIDINONE ANTIBIOTIC DERIVATIVES
  申请人：Gude Markus

  公开号：US20100137290A1

  公开（公告）日：2010-06-03

  The invention relates to antibacterial compounds of formula I wherein R 1 is hydrogen, halogen, hydroxy, alkoxy or cyano; Y 1 and Y 2 each represent CH, one or two of U, V, W and X represent(s) N and the remaining each represent CH or, in the case of X, may also represent CR a , R a being halogen, and, in the case of W, may also represent CR b , or each of U, V, W, X, Y 1 and Y 2 represents CH, or each of U, V, W, X and Y 1 represents CH and Y 2 represents N, or also one or, provided R 1 is hydrogen, two of U, V, W, X, Y 1 and Y 2 represent(s) CRC and the remaining each represent CH, R b being alkoxy, alkoxycarbonyl or alkoxyalkoxy and R c being, each time it occurs, independently represents hydroxy or alkoxy; A-B-D represents a chain of 4 to 6 atoms, which 4 to 6 atoms are seleted from carbon, oxygen and nitrogen and may be substituted; E is one of the following groups: in which Z is CH or N and Q is O or S, or E is a phenyl group which is substituted once or twice in the meta and/or para position(s); and to salts of such compounds.

  本发明涉及式I的抗菌化合物，其中R1为氢、卤素、羟基、烷氧基或氰基；Y1和Y2各自代表CH，一个或两个U、V、W和X代表N，其余各自代表CH，或者在X的情况下，也可以代表CRa，其中Ra为卤素，并且在W的情况下，也可以代表CRb，或者U、V、W、X、Y1和Y2各自代表CH，或者U、V、W、X和Y1各自代表CH，而Y2代表N，或者，如果R1为氢，则一个或两个U、V、W、X、Y1和Y2代表CRC，其余各自代表CH，其中Rb为烷氧基、烷氧羰基或烷氧基烷氧基，Rc每次出现时独立地代表羟基或烷氧基；A-B-D代表4至6个原子的链，这4至6个原子选自碳、氧和氮，并且可以被取代；E是以下组之一：其中Z为CH或N，Q为O或S，或者E为苯基，该苯基在间位和/或对位被取代一次或两次；以及这类化合物的盐。
• [EN] AMINOMETHYL QUINOLONE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOMÉTHYL-QUINOLONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013007676A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula (I): wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  这项发明涉及JNK抑制剂及相应的用于抑制JNK和治疗JNK介导的疾病的方法、配方和组合物。该申请披露了JNK抑制剂，如下所述的化学式(I)：其中变量如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。还披露了用于抑制JNK和治疗JNK介导的疾病等的方法和配方，以及用于制备上述化合物和相应组合物的过程。
• PIPERIDINE DERIVATIVE
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190040039A1

  公开（公告）日：2019-02-07

  The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis , multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.

  本发明的目的是提供一种对结核分枝杆菌、多药耐药结核菌和/或非结核性抗酸杆菌具有优异抗菌活性的化合物。可以利用由化学式[I]表示的化合物（在该化学式中，每个符号如所附规范所述），或其盐来诊断、预防和/或治疗结核病。
• [EN] NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI<br/>[FR] NOUVEAUX COMPOSÉS D'OXADIAZOLE CONTENANT UN CYCLE HÉTÉROAROMATIQUE À 5 CHAÎNONS POUR LA LUTTE OU LA PRÉVENTION CONTRE DES CHAMPIGNONS PHYTOPATHOGÈNES
  申请人：PI INDUSTRIES LTD

  公开号：WO2021033133A1

  公开（公告）日：2021-02-25

  The present invention relates to a compound of formula (I), wherein, R1,A, A5, A6, A7, A8, R12, n and Q are as defined in the detailed description and a process for preparing the compound of formula (I).The present invention also relates to a method for controlling or preventing phytopathogenic fungi.

  本发明涉及一种化合物，其化学式为(I)，其中，R1、A、A5、A6、A7、A8、R12、n和Q如详细描述中所定义，并且涉及制备该化合物的方法。本发明还涉及一种控制或预防植物病原真菌的方法。